News and Breakthroughs

A novel drug called enzalutamide may extend overall survival for men with nonmetastatic, castration-resistant prostate cancer, according to findings from clinical trial published in The New England Journal of Medicine.

A protein called mDia2 is vital for proper bone marrow transplantation, according to a new study.

A genetic screen has revealed previously unknown regulators of Foxp3, a transcription factor that, when deactivated, may improve patient response to aggressive cancers.

Northwestern Medicine scientists have discovered an alternate mechanism for aberrant gene splicing that contributes to T-cell lymphoblastic leukemia, according to a recent study.

June 7, 2020 marked an important milestone for 15-year-old Charlie and his family. For months they’d been planning to celebrate Charlie’s 15th “cancerversary” as a retinoblastoma survivor at their 15th Cancer Survivors’ Celebration Walk & 5K.

The Lurie Cancer Center stands with the Association of American Cancer Institutes and strongly condemns any form of racism and discrimination. Please read the full statement below, urging that these issues be confronted as public health crises. Racism has no place in any civilized society and must end once and for all.

Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will present and discuss the latest clinical research impacting cancer care during the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

A new Northwestern Medicine study found important differences in rare skin lymphomas stemming from their specific cell of origin and clinical presentations, according to findings published in Nature Communications.

Hi, I’m Lauren and I have a Grade III Astrocytoma, a type of brain cancer.

For the first time, advanced prostate cancer has been treated based on the genomic makeup of the cancer, delaying disease progression for patients with a treatment-resistant form of prostate cancer.